- Home
- CGO vs COYA Comparison
CGO vs COYA Comparison
Compare CGO & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGO
- COYA
- Stock Information
- Founded
- CGO 2004
- COYA 2020
- Country
- CGO United States
- COYA United States
- Employees
- CGO N/A
- COYA N/A
- Industry
- CGO Investment Managers
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- CGO Finance
- COYA Health Care
- Exchange
- CGO Nasdaq
- COYA Nasdaq
- Market Cap
- CGO 114.2M
- COYA 107.0M
- IPO Year
- CGO N/A
- COYA 2022
- Fundamental
- Price
- CGO $11.75
- COYA $6.15
- Analyst Decision
- CGO
- COYA Strong Buy
- Analyst Count
- CGO 0
- COYA 4
- Target Price
- CGO N/A
- COYA $16.50
- AVG Volume (30 Days)
- CGO 34.7K
- COYA 59.2K
- Earning Date
- CGO 01-01-0001
- COYA 08-12-2025
- Dividend Yield
- CGO 9.25%
- COYA N/A
- EPS Growth
- CGO N/A
- COYA N/A
- EPS
- CGO N/A
- COYA N/A
- Revenue
- CGO N/A
- COYA $423,452.00
- Revenue This Year
- CGO N/A
- COYA $40.52
- Revenue Next Year
- CGO N/A
- COYA N/A
- P/E Ratio
- CGO N/A
- COYA N/A
- Revenue Growth
- CGO N/A
- COYA N/A
- 52 Week Low
- CGO $7.90
- COYA $4.65
- 52 Week High
- CGO $10.93
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- CGO 55.87
- COYA 51.12
- Support Level
- CGO $11.49
- COYA $5.60
- Resistance Level
- CGO $11.87
- COYA $6.28
- Average True Range (ATR)
- CGO 0.15
- COYA 0.41
- MACD
- CGO 0.01
- COYA -0.04
- Stochastic Oscillator
- CGO 78.95
- COYA 49.11
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.